http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#Head http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#provenance http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#pubinfo http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion http://purl.obolibrary.org/obo/DOID_5844 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5844 http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00934 http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association http://www.w3.org/2000/01/rdf-schema#label Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction. http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00934 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#provenance http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#pubinfo http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig http://purl.org/nanopub/x/hasSignature dhZfRc575bxoQOZR46xb/A1hQM30wLNF885Gm4fvlaKxveGcWkp+GLZY8t9crRv8EWNNVxnevOI2+8hO/puL8insACSBw3USa8YrpMSJlMf44+hIaeP0mpXQ8SfkSeAKfDK1jS3U15hzJaULewrVDSf/m71SP1Dy9j0AE/6gSBs= http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://purl.org/dc/terms/created 2021-08-25T14:13:30.145+02:00 http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY